U.S. markets close in 2 hours 49 minutes
  • S&P 500

    3,372.86
    +62.62 (+1.89%)
     
  • Dow 30

    27,466.49
    +541.44 (+2.01%)
     
  • Nasdaq

    11,176.75
    +219.14 (+2.00%)
     
  • Russell 2000

    1,601.39
    +32.79 (+2.09%)
     
  • Crude Oil

    37.65
    +0.84 (+2.28%)
     
  • Gold

    1,911.10
    +18.60 (+0.98%)
     
  • Silver

    24.32
    +0.29 (+1.19%)
     
  • EUR/USD

    1.1712
    +0.0070 (+0.60%)
     
  • 10-Yr Bond

    0.8860
    +0.0370 (+4.36%)
     
  • GBP/USD

    1.3044
    +0.0126 (+0.98%)
     
  • USD/JPY

    104.5290
    -0.1910 (-0.18%)
     
  • BTC-USD

    13,715.09
    +207.82 (+1.54%)
     
  • CMC Crypto 200

    265.21
    +4.55 (+1.74%)
     
  • FTSE 100

    5,786.77
    +131.80 (+2.33%)
     
  • Nikkei 225

    23,295.48
    +318.35 (+1.39%)
     

Horizon Therapeutics CEO On Success Of Key Drug Tepezza, Acquisition Plans

Horizon Therapeutics on Monday reported a solid quarter with big beats on the top and bottom lines and raised its guidance, thanks in large part to its thyroid eye disease drug Tepezza, which just got regulatory approval in January. Horizon Therapeutics CEO Tim Walbert discusses the quarterly results and what's ahead for the rare-disease therapeutics company.